

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.**

**四川科倫博泰生物醫藥股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6990)**

### **POSTPONEMENT OF CHANGE OF SESSIONS OF BOARD OF DIRECTORS AND SUPERVISORY COMMITTEE**

The terms of the third session of the board of directors (the “**Board**”) and the supervisory committee (the “**Supervisory Committee**”) of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “**Company**”) will expire on February 25, 2025. As the preparation for the change of sessions of the Board and the Supervisory Committee (the “**Change of Sessions**”) is still in progress, in order to ensure the continuity of the work of the Board and the Supervisory Committee, the term of the third session of the Board and Supervisory Committee will be extended. The terms of the committees of the third session of the Board and the senior management of the Company will also be extended accordingly. All the members of the third session of the Board and the Supervisory Committee will continue to fulfill their respective obligations and responsibilities in accordance with the relevant laws and regulations and the articles of association of the Company until the Change of Sessions which is expected to take place at the upcoming annual general meeting of the Company subject to the approval of the shareholders of the Company.

The extended term of the third session of the Board and the Supervisory Committee will not affect the normal operation of the Company. The Company will make further announcement(s) in relation to the Change of Sessions in accordance with the requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited as and when appropriate.

By order of the Board

**Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.**

**LIU Gexin**

*Chairman of the Board and Non-executive Director*

Hong Kong, January 28, 2025

*As at the date of this announcement, the Board comprises Mr. LIU Gexin as the chairman of the Board and non-executive Director, Dr. GE Junyou as executive Director, Mr. LIU Sichuan, Mr. LAI Degui, Mr. FENG Hao, Mr. ZENG Xuebo and Mr. LI Dongfang as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping, and Dr. LI Yuedong as independent non-executive Directors.*